AGBL4: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: AGBL4

NCBI ID: G84871

AGBL4

AGBL4: A Potential Drug Target Or Biomarker for Various Diseases

AGBL4 (protein deglutamylase CCP6) is a protein that is expressed in various tissues throughout the body. It is a key enzyme in the degradation of glutamyl-containing peptides, which are involved in many cellular processes. Recent research has identified AGBL4 as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

AGBL4 is a member of the family of proteins known as glutamyl-proteases (GPros), which are involved in the regulation of protein levels and degradation. These enzymes belong to the CCP (Ca2+-dependent cytoskeleton-associated protein) family 6 (CCP6) . GPros are characterized by the presence of a catalytic active site, which is responsible for the chemical reaction that occurs during protein degradation.

AGBL4 is expressed in a variety of tissues, including muscle, liver, kidney, and brain. It is highly expressed in the liver, which is one of the main sites of protein degradation in the body. In the liver, AGBL4 is involved in the Degradation of a wide variety of proteins, including many involved in cellular signaling pathways.

One of the unique features of AGBL4 is its ability to interact with other proteins. It has been shown to form a complex with several different proteins, including the transcription factor ASXL1 and the protein involved in the detoxification of xenobiotics, called TrxP. These interactions may have important implications for the function of AGBL4 and its role in various cellular processes.

In addition to its role in protein degradation, AGBL4 has also been shown to play a role in the regulation of cellular signaling pathways. It has been shown to be involved in the degradation of several signaling proteins, including the neurotransmitter serotonin and the transcription factor CREB . These effects may help to explain the potential therapeutic benefits of targeting AGBL4 in neurodegenerative diseases.

AGBL4 has also been shown to be involved in the regulation of inflammation. It has been shown to be involved in the degradation of several pro-inflammatory proteins, including the cytokine interleukin-1尾. This may help to explain the potential therapeutic benefits of targeting AGBL4 in autoimmune disorders.

In conclusion, AGBL4 is a protein that has been shown to play a role in a variety of cellular processes throughout the body. Its unique ability to interact with other proteins and its involvement in the regulation of signaling pathways and inflammation make it a promising target for therapeutic intervention. Further research is needed to fully understand the role of AGBL4 in various diseases and to develop effective treatments.

Protein Name: AGBL Carboxypeptidase 4

Functions: Metallocarboxypeptidase that mediates protein deglutamylation of tubulin and non-tubulin target proteins. Catalyzes the removal of polyglutamate side chains present on the gamma-carboxyl group of glutamate residues within the C-terminal tail of tubulin protein. Specifically cleaves tubulin long-side-chains, while it is not able to remove the branching point glutamate. Also catalyzes the removal of polyglutamate residues from the carboxy-terminus of non-tubulin proteins such as MYLK. Mediates the deglutamylation of nucleotidyltransferase CGAS, leading to CGAS antiviral defense response activation (By similarity). Involved in KLF4 deglutamylation which promotes KLF4 proteasome-mediated degradation, thereby negatively regulating cell pluripotency maintenance and embryogenesis (PubMed:29593216)

The "AGBL4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AGBL4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets